2023
Postinfantile Giant Cell Hepatitis in Native and Allograft Livers: A Multi-Institutional Clinicopathologic Study of 70 Cases
Jiao J, Chezar K, Zhang X, Wang D, Cao W, Bindu C, Chen W, Neto A, Henn P, Riahi I, Wang H, Papke D, Zhao L, Xue Y, Liao X, Zhang X. Postinfantile Giant Cell Hepatitis in Native and Allograft Livers: A Multi-Institutional Clinicopathologic Study of 70 Cases. Modern Pathology 2023, 36: 100298. PMID: 37544363, DOI: 10.1016/j.modpat.2023.100298.Peer-Reviewed Original ResearchConceptsPostinfantile giant cell hepatitisAutoimmune liver diseaseGiant cell hepatitisAlkaline phosphatase levelsClinical outcomesPhosphatase levelsLiver diseaseMulti-institutional retrospective studyAssociated with better survivalAssociated with poor survivalClinicopathological characteristics of patientsAdverse prognostic factorAssociated with autoimmune liver diseasesGiant cellsVariable clinical outcomesFollow-up resultsCharacteristics of patientsDistribution of giant cellsOlder ageLiver disease etiologyPrognostic factorsAdvanced fibrosisBetter survivalClinicopathological characteristicsLiver allografts
2022
Impact of secondary mitral regurgitation on survival in atrial and ventricular dysfunction
Mori M, Zogg C, Amabile A, Fereydooni S, Agarwal R, Weininger G, Krane M, Sugeng L, Geirsson A. Impact of secondary mitral regurgitation on survival in atrial and ventricular dysfunction. PLOS ONE 2022, 17: e0277385. PMID: 36548259, PMCID: PMC9778994, DOI: 10.1371/journal.pone.0277385.Peer-Reviewed Original ResearchConceptsSecondary mitral regurgitationVentricular dysfunctionHazard of deathAtrial dysfunctionMitral regurgitationMild secondary mitral regurgitationSevere secondary mitral regurgitationCox proportional hazards modelRisk-adjusted hazardRetrospective cohort studySurvival of patientsProportional hazards modelCohort studyPatient demographicsSeverity strataBetter survivalHazards modelPatientsDysfunctionNatural historyPropensity scoreSeverityDifferent severitySurvivalRegurgitationUtilization and Outcomes of Radiation in Stage IV Esophageal Cancer
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Johung K, Boffa D. Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100429. PMID: 36483656, PMCID: PMC9722471, DOI: 10.1016/j.jtocrr.2022.100429.Peer-Reviewed Original ResearchStage IV esophageal cancerNational Cancer DatabaseEsophageal cancerCancer DatabaseRadiation doseSurvival advantageMedian total radiation dosePropensity score-matched pairsOutcome of radiationRetrospective cohort studyKaplan-Meier analysisTotal radiation doseAppropriate radiation dosePalliative regimensCohort studyMedian ageRadiation administrationSurvival associationsBetter survivalPatientsLocal controlCancerDosePalliationFurther studiesEvolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234
Michikawa C, Torres-Saavedra P, Silver N, Harari P, Kies M, Rosenthal D, Le Q, Jordan R, Duose D, Mallampati S, Trivedi S, Luthra R, Wistuba I, Osman A, Lichtarge O, Foote R, Parvathaneni U, Hayes D, Pickering C, Myers J. Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Advances In Radiation Oncology 2022, 7: 100989. PMID: 36420184, PMCID: PMC9677209, DOI: 10.1016/j.adro.2022.100989.Peer-Reviewed Original ResearchDisease-free survivalCisplatin armDocetaxel armOverall survivalPrognostic markerRadiation therapyHigh-risk pathologic featuresHuman papillomavirus-negative headPhase 2 clinical trialPhase 2 studyBetter overall survivalLow-risk groupReliable prognostic markersEvolutionary action scoreAdvanced HNSCCAdjuvant treatmentResection samplesClinical outcomesDistant metastasisPathologic featuresPoor outcomeNeck cancerClinical trialsTreatment outcomesBetter survival
2021
Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer
Saridakis A, Berger ER, Harigopal M, Park T, Horowitz N, Le Blanc J, Zanieski G, Chagpar A, Greenup R, Golshan M, Lannin DR. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer. Annals Of Surgical Oncology 2021, 28: 5610-5616. PMID: 34426884, DOI: 10.1245/s10434-021-10518-9.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalCancer-specific survivalHigh-grade tumorsMolecular subtypesApocrine carcinomaBreast cancerBetter survivalHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Triple-negative breast cancerRare breast cancerEnd Results (SEER) databaseGrowth factor receptor 2Triple-negative patientsTriple-negative cancersLow-grade tumorsFactor receptor 2Life table methodApocrine tumorsLuminal patientsWorse survivalClinicopathologic featuresResults databaseAggressive featuresReceptor 2Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States
Wang X, Zeidan AM, Wang R, Bewersdorf JP, Zhang C, Podoltsev NA, Huntington SF, Gore SD, Ma X. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & Lymphoma 2021, 62: 2438-2447. PMID: 33899659, DOI: 10.1080/10428194.2021.1913142.Peer-Reviewed Original ResearchConceptsPopulation-based studyDNA methyltransferase inhibitorRARS patientsRefractory anemiaRing sideroblastsRed blood cell transfusion independenceEnd Results-Medicare databaseLower-risk myelodysplastic syndromesPopulation-based cohortMethyltransferase inhibitorRBC-TIMedian durationMedian survivalOlder patientsTransfusion independenceTreatment initiationMyelodysplastic syndromeClinical effectivenessBetter survivalLenalidomideTreatment groupsPatientsRS statusOlder adultsAnemia5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING
Tian J, Zhang D, Kurbatov V, Wang Q, Wang Y, Fang D, Wu L, Bosenberg M, Muzumdar MD, Khan S, Lu Q, Yan Q, Lu J. 5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING. The EMBO Journal 2021, 40: embj2020106065. PMID: 33615517, PMCID: PMC8013832, DOI: 10.15252/embj.2020106065.Peer-Reviewed Original ResearchConceptsAnti-tumor immunityTumor burdenSubsequent type I interferon productionHigh STING expressionIntratumoral T cellsT-cell depletionType I interferon productionI interferon productionLoss of STINGImmunocompetent hostsColorectal specimensT cellsSTING expressionBetter survivalHigh doseTherapeutic effectivenessHuman colorectal specimensMelanoma tumorsInterferon productionChemotherapeutic drugsMurine colonImmunityEfficacyStingsColon
2020
Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study.
Cheng E, Hung P, Wang SY. Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. Journal Of The National Comprehensive Cancer Network 2020, 18: 729-736. PMID: 32502978, DOI: 10.6004/jnccn.2020.7529.Peer-Reviewed Original ResearchConceptsHospital referral regionsCurative treatmentHepatocellular carcinomaIncidence of HCCCox proportional hazards modelSEER-Medicare studyPercutaneous ethanol injectionHepatitis B virusProportional hazards modelMore comorbiditiesSurgical resectionSurvival benefitTreatment patternsSEER-MedicareB virusRadiofrequency ablationEthanol injectionTreatment utilizationReferral regionsBetter survivalLower riskHazards modelPatientsSurvivalTreatmentEpidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map
Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews 2020, 42: 100706. PMID: 32517877, DOI: 10.1016/j.blre.2020.100706.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic myeloid leukemiaPolycythemia veraEssential thrombocythemiaMyeloproliferative neoplasmsClassical myeloproliferative neoplasmsPrimary myelofibrosisIncidence of CMLEnd Results program dataTyrosine kinase inhibitor therapyCML patient outcomesClonal myeloid disordersKinase inhibitor therapyPotential etiological roleInhibitor therapyMale genderRisk factorsPatient outcomesMyeloid leukemiaPMF patientsBetter survivalGeneral populationEtiological roleMyeloid disordersMolecular abnormalitiesEpidemiological literatureAssociation between Hospital volume of cardiopulmonary resuscitation for in-hospital cardiac arrest and survival to Hospital discharge
Akintoye E, Adegbala O, Egbe A, Olawusi E, Afonso L, Briasoulis A. Association between Hospital volume of cardiopulmonary resuscitation for in-hospital cardiac arrest and survival to Hospital discharge. Resuscitation 2020, 148: 25-31. PMID: 31945429, DOI: 10.1016/j.resuscitation.2019.12.037.Peer-Reviewed Original ResearchConceptsNational Inpatient SampleHospital cardiac arrestHospital dischargeCase volumeCardiac arrestCases of IHCAHospital case volumeMedian case volumeNon-significant trendNon-linear associationHospital volumeHome dischargeHospital CPRYounger patientsInpatient SampleCardiopulmonary resuscitationHigh comorbidityBetter survivalFirst quartileIHCAHospitalQuartilePatientsStudy periodSurvival
2019
Hemodialysis and peritoneal dialysis access related outcomes in the pediatric and adolescent population
Arhuidese I, Wanogho J, Faateh M, Aji E, Rideout D, Malas M. Hemodialysis and peritoneal dialysis access related outcomes in the pediatric and adolescent population. Journal Of Pediatric Surgery 2019, 55: 1392-1399. PMID: 31784099, DOI: 10.1016/j.jpedsurg.2019.09.017.Peer-Reviewed Original ResearchConceptsArteriovenous fistulaPeritoneal dialysisHD cathetersCatheter useAssociated with better patencyUnited States Renal Database SystemAssociated with better survivalAssociated with high mortalityMultivariate Cox regressionRetrospective cohort studyPersistent useInitiation of HDHD to PDPD catheterCatheter survivalSecondary patencyPatients 0Pediatric patientsBetter survivalPrimary assistedRisk-adjusted mortalityPediatric populationRetrospective analysisTransplantation potentialDialysis accessEffect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart Failure
Griffin M, Rao VS, Fleming J, Raghavendra P, Turner J, Mahoney D, Wettersten N, Maisel A, Ivey-Miranda JB, Inker L, Tang WHW, Wilson FP, Testani JM. Effect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart Failure. The American Journal Of Cardiology 2019, 124: 1707-1711. PMID: 31601358, PMCID: PMC6959849, DOI: 10.1016/j.amjcard.2019.08.034.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureDecompensated heart failureHeart failureImproved survivalHigher loop diuretic dosesLoop diuretic dosesNet fluid lossPlasma volume reductionAggressive decongestionAggressive diuresisPostdischarge survivalDiuretic dosesPostdischarge outcomesSerum creatinineHospital treatmentHospital parametersBetter survivalCreatinineHemoconcentrationPatient carePatientsSurvivalLonger lengthVolume reductionTreatmentMicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3
Han R, Chen X, Li Y, Zhang S, Li R, Lu L. MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3. Cancer Management And Research 2019, 11: 2963-2976. PMID: 31114344, PMCID: PMC6489561, DOI: 10.2147/cmar.s202664.Peer-Reviewed Original ResearchPrimary hepatocellular carcinomaHepatocellular carcinomaKaplan-Meier survival curvesNormal tissuesSNU-449Cell proliferationLiver cancer cellsQuantitative reverse transcription PCROverall survivalPatient survivalCaspase-3 activityHCC patientsReverse transcription-PCRAntineoplastic roleBetter survivalTreatment groupsTumor aggressivenessRT-qPCR resultsSurvival analysisSurvival curvesMeta-AnalysisCASP3 activityMicroRNA-34aCancer cellsCell invasion
2018
Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR
Lee E, Collazo-Lorduy A, Castillo-Martin M, Gong Y, Wang L, Oh W, Galsky M, Cordon-Cardo C, Zhu J. Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. Oncogene 2018, 37: 5858-5872. PMID: 29970902, PMCID: PMC6212417, DOI: 10.1038/s41388-018-0367-0.Peer-Reviewed Original ResearchConceptsMiR-106b-5pMiRNA expression signaturesBladder cancerMiR-532MiR-106Resistance to cisplatin-based chemotherapyPrognostic biomarkerMuscle-invasive bladder cancerAssociated with better survivalCisplatin-based chemotherapyHeterogeneous clinical outcomesMiRNA expressionMiRNAsPersonalized treatment optionsBladder tumorsPrognostic groupsBasal subtypeBetter survivalPrognostic markerTumor typesClinical outcomesTreatment optionsTumor progressionCancer Genome AtlasMiRNA activityVentricular Myocardial Fat: An Unexpected Biomarker for Long-term Survival?
Bader AS, Levsky JM, Zalta BA, Shmukler A, Gohari A, Jain VR, Chernyak V, Lovihayeem M, Bellin EY, Haramati LB. Ventricular Myocardial Fat: An Unexpected Biomarker for Long-term Survival? European Radiology 2018, 29: 241-250. PMID: 29948081, DOI: 10.1007/s00330-018-5546-4.Peer-Reviewed Original ResearchConceptsMyocardial fatMI groupCharlson scoreCause mortalityPrior MIRisk stratificationChest CTBetter survivalChronic myocardial infarction patientsTraditional risk prediction modelsCox proportional hazards analysisNon-contrast chest CTMethodsA retrospective cohortCardiovascular risk factorsAge-matched patientsProportional hazards analysisTraditional cardiovascular riskNet reclassification improvementMyocardial infarction patientsUrban academic centerNon-contrast CTMeaningful prognostic valueLong-term survivalRisk prediction modelAdjusted hazard
2017
Regional Medicare Expenditures and Survival Among Older Women With Localized Breast Cancer
Tannenbaum S, Soulos PR, Herrin J, Mougalian S, Long JB, Wang R, Ma X, Gross CP, Xu X. Regional Medicare Expenditures and Survival Among Older Women With Localized Breast Cancer. Medical Care 2017, 55: 1030-1038. PMID: 29068906, PMCID: PMC5863278, DOI: 10.1097/mlr.0000000000000822.Peer-Reviewed Original ResearchConceptsBreast cancer careHospital referral regionsNonmetastatic breast cancerBreast cancerCancer careMedicare beneficiariesMedicare expendituresCancer expendituresBetter survivalEnd Results-MedicareRetrospective cohort studyPatients 3 yearsClinical characteristicsCohort studyOverall survivalCancer stagePatient outcomesOutcome measuresReferral regionsOlder womenSignificant associationStage IIBivariate analysisCancerQuintileOvercoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome
Zeidan AM, Pullarkat VA, Komrokji RS. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. Critical Reviews In Oncology/Hematology 2017, 117: 57-66. PMID: 28807236, DOI: 10.1016/j.critrevonc.2017.07.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIron chelation therapyIron overloadMyelodysplastic syndromeFrequent red blood cell transfusionsLower-risk myelodysplastic syndromesRed blood cell transfusionLow-risk MDS patientsHeterogeneous hematopoietic neoplasmsRandomized trial evidenceBlood cell transfusionAcute myeloid leukemiaTissue iron depositionCell transfusionSupportive careMDS patientsTrial evidenceMyeloid leukemiaChelation therapyThalassemia patientsIneffective erythropoiesisBetter survivalPatientsEndocrine toxicityIron depositionHematopoietic neoplasmsImmune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability.
Gyorffy B, Bottai G, Nagy A, Pusztai L, Santarpia L. Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability. Journal Of Clinical Oncology 2017, 35: 1096-1096. DOI: 10.1200/jco.2017.35.15_suppl.1096.Peer-Reviewed Original ResearchTriple-negative breast cancerCytotoxic T cellsNatural killerDendritic cellsT cellsImmune infiltrationBreast cancerTNBC samplesB cellsImmune gene signaturesOverall good prognosisKaplan-Meier analysisMann-Whitney U testChromosomal instabilityWarrants further investigationImmune infiltratesBetter prognosisTNBC patientsTNBC tumorsImmune metagenesMS tumorsImmune responseBetter survivalImmune componentsTherapeutic strategies
2016
Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction
Samad Z, Vora AN, Dunning A, Schulte PJ, Shaw LK, Al-Enezi F, Ersboll M, McGarrah RW, Vavalle JP, Shah SH, Kisslo J, Glower D, Harrison JK, Velazquez EJ. Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction. European Heart Journal 2016, 37: 2276-2286. PMID: 26787441, PMCID: PMC5841220, DOI: 10.1093/eurheartj/ehv701.Peer-Reviewed Original ResearchConceptsAortic valve surgerySevere aortic stenosisModerate aortic stenosisAortic stenosisValve surgeryMean gradientMultivariable Cox modelVentricular systolic dysfunctionCoronary artery bypassHigh-risk cohortCurrent practice patternsArtery bypassCause mortalityEchocardiographic databaseSystolic dysfunctionVentricular dysfunctionMultivariable adjustmentTranscatheter approachMedical therapyPractice patternsBetter survivalCABGCox modelPatientsLower mortalityLIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis
Lu L, Katsaros D, Canuto EM, Biglia N, Risch HA, Yu H. LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis. Gynecologic Oncology 2016, 141: 121-127. PMID: 26751131, DOI: 10.1016/j.ygyno.2015.12.035.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancer prognosisOvarian cancer prognosisMolecular subtypesCancer prognosisSurvival analysisMultivariate Cox regression modelKaplan-Meier survival curvesEpithelial ovarian cancer tissuesCox regression modelEpithelial ovarian cancerReduced relapse riskOvarian cancer tissuesIGF-II mRNAQuantitative reverse transcription PCRRelapse riskReverse transcription-PCROvarian cancerBetter survivalCancer tissuesLin-28BSurvival curvesClinical implicationsIGFPrognosisSubtypes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply